Value-creating divestment supports AstraZeneca’s focus on three main therapy areas Pfizer’s dedicated focus on infectious diseases will extend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics business
AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development programme Fast Track status for the treatment of uncomplicated gonorrhoea, which is increasingly resistant to existing antibiotics and poses a serious global public health threat.
AstraZeneca lanserar Zinforo (ceftarolinfosamil), ett nytt antibiotikum för behandling av vuxna patienter med komplicerade infektioner i hud och mjukvävnad eller med samhällsförvärvad lunginflammation. Zinforo är det enda antibiotikum av cefalosporintyp i Europa med bevisad klinisk effekt mot meticillinresistenta stammar av gula stafylokocker (MRSA).